Respiratory Health Cross-Sector
Webinar Recordings

white paper cut out in the shape of a pair of lungs

Opportunities and Tools to Investigate
Occupational Risk Factors for COPD

September 20-21, 2022

Day 1 – Tuesday, September 20, 2022

Day 1, Session 1
Keynote address, and case studies on diagnosing and managing work-related COPD

Day 1, Session 2
COPD not due to smoking, and epidemiologic studies of work-related COPD

Day 2 – Tuesday, September 21, 2022

Day 2, Session 1
Findings from basic/mechanistic research relevant to work-related COPD

Day 2, Session 2
Research opportunities and tools for studying work-related COPD

Continuing Education (CE) Credits for WD4613 – Opportunities and Tools to Investigate Occupational Risk Factors for COPD

This enduring activity is designed to inform participants about the contributions of occupational exposures to work-related COPD to improve its identification and management.

At the conclusion of the session, the participant should be able to:

  1. Describe the clinical challenges in diagnosing work-related COPD.
  2. Describe the management of work-related COPD.
  3. Describe the differences between COPD cases attributed to occupational exposures and those attributed to cigarette smoking.
  4. Describe epidemiologic evidence for the contribution of occupational exposures to work-related COPD.
  5. Describe evidence for the course of work-related COPD in individuals.
  6. Discuss conducting research on work-related COPD.
  7. Describe the importance of interprofessional collaboration in addressing work-related COPD.


  • Paul Henneberger, MPH, ScD, Senior Science Advisor, Respiratory Health Division, NIOSH
  • Paul Blanc, MD, MPH, Professor, UCSF School of Medicine
  • Susan Tarlo, MB BS, Professor, University of Toronto
  • David Fishwick, MBChB, Professor, University of Sheffield
  • Rafael E. de la Hoz, MD, MPH, MSc, Professor, Icahn School of Medicine at Mount Sinai
  • David Mannino, MD, Medical Director, COPD Foundation
  • Theodore Lytras, MD, MPH, PhD, Professor, School of Medicine, European Univ. Cyprus
  • Chris Carlsten, MD, MPH, Professor, Univ. of British Columbia
  • Farrah Kheradmand, MD, Professor, Baylor College of Medicine
  • Jacek Mazurek, MD, PhD, Supervisor Research Epidemiologist, Respiratory Health Division, NIOSH
  • Ravi Kalhan, MD, MS, Professor, Northwestern Univ. Feinberg School of Medicine
  • George O’Connor, MD, MS, Professor, Boston Univ. School of Medicine
  • Nadia Hansel, MD, MPH, Associate Dean of Research, Johns Hopkins School of Medicine

Course Summary (

Computer Hardware; Internet Connection; Browser


Physicians, Registered Nurses


This activity is Web on Demand.

Office of the NIOSH Respiratory Health Division, (304) 285-5755

Jointly accredited provider icon

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Centers for Disease Control and Prevention designates this activity for 6.75 nursing contact hours.

In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, presenters wish to disclose they have no financial relationship(s) with ineligible companies with the exception of Dr. Nadia Hansel who wishes to disclose Astra Zeneca (Research Grant / Advisory Board), Boehringer Ingelheim (Research Grant), GSK (Advisory Board), and NIH (Research Grant); Dr. Ravi Kalhan who wishes to disclose GlaxoSmithKline (Consultant/Speaker), AstraZeneca (Consultant/Speaker), Boehringer Ingelheim (Consultant), and CVS Caremark (Consultant); Dr. David Mannino who wishes to disclose AstraZeneca (Consultant) and Up to Date (Consultant); and Dr. George O’Connor who wishes to disclose Dicerna (Data and Safety Monitoring Committee) and Marinari (Speaker at conference funded by unrestricted education grant).

All of the relevant financial relationships listed for these individuals have been mitigated.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept commercial support for this continuing education activity.

Instructions for Obtaining Continuing Education (CE)
To receive continuing education (CE) for WD4613Opportunities and Tools to Investigate Occupational Risk Factors for COPD please visit TCEO and follow these 9 Simple Steps.

Complete the activity by viewing all 4 sections of the webinar: the 2 sessions on Day 1, and the 2 sessions on Day 2

Complete the Evaluation at
Pass the posttest at 71% at

FEES: No fees are charged for CDC’s CE activities.
For any additional information or questions related to the Course Access Code or CE information, please contact: